Security Snapshot

Coherus Oncology, Inc. - Common Stock (CHRS) Institutional Ownership

CUSIP: 19249H103

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

93

Shares (Excl. Options)

46.54MFull value: 46,538,628 · shares · 30 Sep 2026

Price

$1.21

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-5,023,426
Value change
-$7,035,903
Number of holders
93
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
154,050,897
SEC-reported price per share
$0.90
Insider filing price
$0.90
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CHRS - Coherus Oncology, Inc. - Common Stock is tracked under CUSIP 19249H103.
  • 93 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 144 to 93 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $98.44MFull value: $98,439,060 · USD · 30 Jun 2026
    to
    $56.19MFull value: $56,191,032 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 93 institutions filings for Q3 2026.

Open SEC evidence

Security key

19249H103

13F reference period

Q3 2026

13F holders

93

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
CHRS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Timothy G. Youngquist 2020 Irrevocable Trust 8.3% +0.38% $21,803,868 -$68,400 12,750,800 -0.31% Timothy G. Youngquist 2020 Irrevocable Trust 31 Mar 2026
BlackRock, Inc. 5.8% +18% $12,508,933 +$2,236,767 8,934,952 +22% BlackRock, Inc. 30 Jun 2026
Bering Partners II, L.P. 6.5% $12,468,441 7,602,708 Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
SATTERFIELD THOMAS A JR 4.6% -12% $11,711,700 +$1,555,621 6,930,000 +15% Thomas A. Satterfield, Jr. 31 Mar 2026
Rubric Capital Management LP 4.6% $5,258,754 5,258,754 Rubric Capital Management LP 31 Dec 2024
As of 30 Sep 2026, 93 institutional investors reported holding
46.54MFull value: 46,538,628 · shares · 30 Sep 2026
shares of Coherus Oncology, Inc. - Common Stock (CHRS). This represents 30% of the company’s total
154.05MFull value: 154,050,897 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
29%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Timothy G. Youngquist 2020 Irrevocable Trust 8.5% 13,050,623 3.1% $15,791,254
VANGUARD CAPITAL MANAGEMENT LLC 3.6% 5,598,339 0% $6,773,990
SAMSARA BIOCAPITAL, LLC 2.2% 3,383,565 0.39% $4,094,114
GEODE CAPITAL MANAGEMENT, LLC 2% 3,098,735 0% $3,750,533
Kohlberg Kravis Roberts & Co. L.P. 2% 3,036,076 0.07% $3,562,484
STATE STREET CORP 1.6% 2,426,779 0% $2,936,403
CM Management, LLC 1.4% 2,100,000 1.7% $2,541,000
GOLDMAN SACHS GROUP INC 1.3% 1,995,469 0% $2,414,517
C WorldWide Group Holding A/S 1.3% 1,928,464 0.06% $2,333,000
Hudson Bay Capital Management LP 1.1% 1,733,000 0.01% $2,096,930
RENAISSANCE TECHNOLOGIES LLC 0.61% 941,828 0% $1,139,612
PANAGORA ASSET MANAGEMENT INC 0.59% 907,876 0% $1,098,530
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.58% 900,000 0% $1,089,000
VANGUARD FIDUCIARY TRUST CO 0.58% 886,320 0% $1,072,447
VANGUARD PORTFOLIO MANAGEMENT LLC 0.54% 833,694 0% $1,008,770
BANK OF AMERICA CORP /DE/ 0.28% 424,202 0% $513,285
Invesco Ltd. 0.24% 371,021 0% $448,935
ALLIANCEBERNSTEIN L.P. 0.14% 221,900 0% $268,499
Empowered Funds, LLC 0.11% 175,000 0% $211,750
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 0.1% 159,990 0% $193,587
Tyche Wealth Partners LLC 0.09% 144,202 0.02% $174,484
Summit Financial, LLC 0.07% 114,834 0% $138,949
Corient Private Wealth LP 0.06% 100,005 0% $121,007
XTX Topco Ltd 0.06% 85,247 0% $103,149
PVG ASSET MANAGEMENT CORP 0.05% 74,160 0.06% $89,734

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
48
Headline period
Q3 2026
Rows shown
1-25 of 48
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 46,538,628 $56,191,032 -$7,035,903 $1.21 93
2026 Q2 70,302,351 $98,439,060 -$2,917,889 $1.40 144
2026 Q1 71,564,602 $120,792,356 +$29,462,872 $1.69 158
2025 Q4 51,226,608 $72,711,760 -$2,068,458 $1.42 126
2025 Q3 51,511,878 $84,436,218 -$2,969,339 $1.64 110
2025 Q2 55,358,578 $40,439,575 -$4,928,963 $0.73 109
2025 Q1 62,082,313 $50,064,190 -$6,457,989 $0.81 114
2024 Q4 65,594,814 $90,489,403 -$12,493,801 $1.38 121
2024 Q3 76,943,748 $79,924,458 -$11,982,900 $1.04 127
2024 Q2 82,580,425 $142,867,620 -$603,275 $1.73 132
2024 Q1 82,494,208 $197,162,680 -$5,908,937 $2.39 134
2023 Q4 81,477,441 $271,309,409 -$37,399,801 $3.33 153
2023 Q3 92,968,604 $347,619,918 +$14,526,156 $3.74 168
2023 Q2 86,685,207 $370,290,994 +$30,644,927 $4.27 159
2023 Q1 78,433,333 $536,456,842 -$2,030,485 $6.84 163
2022 Q4 78,672,183 $622,985,097 +$2,380,758 $7.92 160
2022 Q3 77,664,501 $746,258,214 -$14,908,210 $9.61 168
2022 Q2 78,904,235 $571,951,639 +$12,362,063 $7.24 171
2022 Q1 75,936,074 $979,679,788 -$19,093,537 $12.91 172
2021 Q4 76,732,060 $1,226,275,602 +$9,148,757 $15.96 190
2021 Q3 76,118,247 $1,224,124,361 -$23,896,897 $16.07 182
2021 Q2 77,861,825 $1,077,307,964 -$38,365,571 $13.83 184
2021 Q1 80,296,427 $1,174,206,082 -$126,382,516 $14.61 201
2020 Q4 86,846,381 $1,509,532,138 +$7,068,870 $17.38 191
2020 Q3 87,967,283 $1,615,322,964 -$17,575,985 $18.34 200
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .